For the first time in hepatocellular carcinoma (HCC), researches have demonstrated the effectiveness of Nrf2 in protecting cells from ferroptosis, this pathway can also be used by ferroptosis activators including sorafenib, which stabilizes NFE2L2 in human HCC cells by inhibiting the formation of NFE2L2-KRAP1 complexes. Here, NFE2L2 is linked to hepatocellular carcinoma.